keyword
MENU ▼
Read by QxMD icon Read
search

Bioresorbable stent

keyword
https://www.readbyqxmd.com/read/29901443/device-specificity-of-vascular-healing-following-implantation-of-bioresorbable-vascular-scaffolds-and-bioabsorbable-polymer-metallic-drugeluting-stents-in-human-coronary-arteries-the-estrofa-oct-bvs-vs-bp-des-study
#1
Jose Maria de la Torre Hernandez, Nieves Gonzalo, Imanol Otaegui, Jose R Rumoroso, Hipólito Gutiérrez, Fernando Alfonso, Gerard Marti, Ana Serrador Frutos, Salvatore Brugaletta, Antonio Gomez Menchero, Tamara Garcia Camarero, Corina Biagioni, Javier Escaned
AIMS: We sought to compare vascular healing with bioresorbable everolimus-eluting vascular scaffolds (BVS) and drug-eluting stents with bioabsorbable polymers (BP-DES) at 6 and 12 months implanted both in same patients. METHODS AND RESULTS: Multicenter and prospective study including patients with at least two comparable lesions to treat. In every patient both BVS and BP-DES (Synergy™, Orsiro™ or Biomatrix Flex™) were implanted by lesion randomization. Patients included were evaluated with optical coherence tomography at 6 or 12 months (2:1)...
June 12, 2018: EuroIntervention
https://www.readbyqxmd.com/read/29887475/-full-plastic-jacket-with-everolimus-eluting-absorb-bioresorbable-vascular-scaffolds-clinical-outcomes-in-the-multicenter-prospective-rai-registry-clinicaltrials-gov-identifier-nct02298413
#2
Giuseppe Tarantini, Giulia Masiero, Luca Nai Fovino, Marco Mojoli, Attilio Varricchio, Bruno Loi, Roberto Gistri, Leonardo Misuraca, Gabriele Gabrielli, Bernardo Cortese, Francesco Pisano, Luciano Moretti, Gabriele Tumminello, Zoran Olivari, Pietro Mazzarotto, Alessandro Colombo, Paolo Calabrò, Annamaria Nicolino, Paola Tellaroli, Donatella Corrado, Alessandro Durante, Giuseppe Steffenino
OBJECTIVES: The objective of this study was to investigate mid-term clinical outcomes of patients treated with 'full-plastic jacket' (FPJ) everolimus-eluting Absorb bioresorbable vascular scaffold (BRS) implantation. BACKGROUND: FPJ with BRS may represent an interesting option for patient with diffuse coronary artery disease (CAD), but data on the clinical impact of FPJ using the Absorb BRS are scant. METHODS: FPJ was defined as the implantation of >56 mm of overlapping BRS in at least one vessel...
September 1, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29862725/-research-progress-of-bioresorbable-scaffold
#3
Qing Liu, Shujun Cui, Qinghong Zhao, Ming Chen, Bo Zheng, Yong Huo
Bioresorbable scaffold (BRS) represents a new technique for percutaneous coronary intervention (PCI). Through providing temporary support to the vessel, it guarantees patency and acute benefits of the vessel in the early treatment stage. When completing its "mission", BRS gradually disappears by resorption. So it allows late vessel positive remodeling without "metal cage" effect and leaves only healed natural vessel after the full absorption, especially in the bifurcation lesion, the branch of the vessels can eventually achieve stent-free interference...
September 30, 2017: Zhongguo Yi Liao Qi Xie za Zhi, Chinese Journal of Medical Instrumentation
https://www.readbyqxmd.com/read/29845812/-bioresorbable-vascular-scaffold-a-focused-review-on-development-and-preclinical-studies
#4
Linnan Ke, Yuanli Huang, Li Liu, Xiaojie Duan, Xiaoming Feng, Chunren Wang
Bioresorbable vascular scaffolds(BVS) are new treatment strategies of percutaneous coronary intervention. They have been introduced to overcome limitations of bare metal stents (BMS) and drug-eluting stents(DES), since they provide temporary scaffolding and then disappear, liberate the treated vessel from cage. In this article, we review the current status and problems of BVS, various tests required before gaining regulatory approval for clinical use.
February 8, 2018: Zhongguo Yi Liao Qi Xie za Zhi, Chinese Journal of Medical Instrumentation
https://www.readbyqxmd.com/read/29843465/coronary-stents-history-design-and-construction
#5
REVIEW
Torrey Schmidt, J Dawn Abbott
The history of percutaneous coronary intervention (PCI) is marked by rapid technological advancements that have taken place over the past 40 years. After a period of balloon angioplasty, which was marred by risk of abrupt vessel closure and vessel recoil, balloon expandable metal alloy stents were the mainstay of PCI. The introduction of drug eluting stents (DES) targeted in-stent restenosis, a common mode of stent failure, and ushered in the current PCI era. Since the first generation of DES, advances in polymer science and stent design have advanced the field...
May 29, 2018: Journal of Clinical Medicine
https://www.readbyqxmd.com/read/29805111/long-term-coronary-functional-assessment-of-the-infarct-related-artery-treated-with-everolimus-eluting-bioresorbable-scaffolds-or-everolimus-eluting-metallic-stents-insights-of-the-trofi-ii-trial
#6
Josep Gomez-Lara, Salvatore Brugaletta, Luis Ortega-Paz, Bert Vandeloo, Elisabetta Moscarella, Miguel Salas, Rafael Romaguera, Gerard Roura, José L Ferreiro, Luis Teruel, Montserrat Gracida, Stephan Windecker, Patrick W Serruys, Joan-Antoni Gomez-Hospital, Manel Sabaté, Angel Cequier
OBJECTIVES: The study sought to compare the vasomotor and microcirculatory function of the infarct-related artery (IRA) between bioresorbable vascular scaffolds (BVS) and everolimus-eluting stents (EES) at 3 years. BACKGROUND: The ABSORB STEMI TROFI II study showed similar outcomes between BVS and EES in the context of ST-segment elevation myocardial infarction at 3 years. METHODS: Sixty-three consecutive event-free patients of the randomized TROFI II study were screened to undergo coronary angiography with vasomotor, microcirculatory, and optical coherence tomography (OCT) examination at 3 years...
May 17, 2018: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/29790479/long-term-clinical-outcomes-after-bioresorbable-and-permanent-polymer-drug-eluting-stent-implantation-final-five-year-results-of-the-century-ii-randomised-clinical-trial
#7
William Wijns, Mariano Valdes-Chavarri, Gert Richardt, Raul Moreno, Andrés Íñiguez-Romo, Emanuele Barbato, Didier Carrié, Kenji Ando, Béla Merkely, Ran Kornowski, Hélène Eltchaninoff, Sinisa Stojkovic, Shigeru Saito
AIMS: The aim of this study was to establish the long-term safety and efficacy of a sirolimus-eluting stent with bioresorbable polymer (BP-SES; Ultimaster) by comparison with an everolimus-eluting stent with permanent polymer (PP-EES; XIENCE). METHODS AND RESULTS: CENTURY II (Clinical Evaluation of New Terumo Drug-Eluting Coronary Stent System in the Treatment of Patients with Coronary Artery Disease) is a large-scale, prospective, multicentre, randomised single-blind, controlled, non-inferiority trial conducted at 58 study sites globally, including Europe, Japan and Korea, powered to prove non-inferiority for freedom from target lesion failure (TLF: cardiac death, target vessel-related myocardial infarction [MI] and target lesion revascularisation) at nine months...
May 23, 2018: EuroIntervention
https://www.readbyqxmd.com/read/29786537/complete-two-year-follow-up-with-formal-non-inferiority-testing-on-primary-outcomes-of-the-aida-trial-comparing-the-absorb-bioresorbable-scaffold-with-the-xience-drug-eluting-metallic-stent-in-routine-pci
#8
Ruben Yannick G Tijssen, Robin P Kraak, Sjoerd H Hofma, Rene J van der Schaaf, Karin Arkenbout, Auke Weevers, Joelle Elias, Ivo M van Dongen, Karel T Koch, Jan Baan, Marije Vis, Robbert J de Winter, Jan J Piek, Jan G P Tijssen, Jose P S Henriques, Joanna J Wykrzykowska
AIMS: The aim of this report of the AIDA trial is to provide full two-year outcomes for the primary endpoint of target vessel failure (TVF) and an update on device thrombosis. METHODS AND RESULTS: AIDA was a single-blind, multicentre, investigator-initiated, non-inferiority, randomised (1:1) clinical trial. At complete two-year follow-up, the primary endpoint of TVF had occurred in 100 patients in the Absorb BVS arm versus 90 patients in the XIENCE EES arm (HR 1...
May 22, 2018: EuroIntervention
https://www.readbyqxmd.com/read/29775814/composite-self-expanding-bioresorbable-prototype-stents-with-reinforced-compression-performance-for-congenital-heart-disease-application-computational-and-experimental-investigation
#9
Fan Zhao, Wen Xue, Fujun Wang, Laijun Liu, Haoqin Shi, Lu Wang
Stents are vital devices to treat vascular stenosis in pediatric patients with congenital heart disease. Bioresorbable stents (BRSs) have been applied to reduce challenging complications caused by permanent metal stents. However, it remains almost a total lack of BRSs with satisfactory compression performance specifically for children with congenital heart disease, leading to importantly suboptimal effects. In this work, composite bioresorbable prototype stents with superior compression resistance were designed by braiding and annealing technology, incorporating poly (p-dioxanone) (PPDO) monofilaments and polycaprolactone (PCL) multifilament...
May 8, 2018: Journal of the Mechanical Behavior of Biomedical Materials
https://www.readbyqxmd.com/read/29774520/implantation-of-bioresorbable-scaffolds-under-guidance-of-optical-coherence-tomography-feasibility-and-pilot-clinical-results-of-a-systematic-protocol
#10
Juan Luis Gutiérrez-Chico, Carlos Cortés, Michele Schincariol, Ula Limon, Meric Yalcinli, María-Alexandra Durán-Cortés, Milosz Jaguszewski
BACKGROUND: We hypothesise that a comprehensive optical coherence tomography (OCT)-guided implantation protocol for bioresorbable scaffolds (BRS) might improve expansion and apposition, thus translating into better clinical outcomes, particularly reducing thrombotic events. METHODS: Patients considered suitable for BRS therapy in de novo coronary lesions underwent OCT. The predominant type of plaque was classified as lipidic, fibrous or calcific, undergoing tailored plaque preparation accordingly...
May 18, 2018: Cardiology Journal
https://www.readbyqxmd.com/read/29743023/three-years-outcomes-of-diabetic-patients-treated-with-coronary-bioresorbable-scaffolds
#11
Remzi Anadol, Katharina Schnitzler, Liv Lorenz, Melissa Weissner, Helen Ullrich, Alberto Polimeni, Thomas Münzel, Tommaso Gori
BACKGROUND: Diabetes is among the strongest predictors of outcome after coronary artery stenting and the incidence of negative outcomes is still high in this specific group. Data of long-term outcomes comparing diabetic patients with non-diabetic patients treated with bioresorbable scaffolds are still incomplete. This work evaluates the long-term outcomes after implantation of a coronary bioresorbable scaffold (BRS) in diabetic patients compared to non-diabetics. METHODS: Patients who received at least one Absorb BRS in the time of May 2012 to December 2014 were enrolled into this single-center registry...
May 10, 2018: BMC Cardiovascular Disorders
https://www.readbyqxmd.com/read/29742143/mid-term-outcomes-of-the-absorb-bvs-versus-second-generation-des-a-systematic-review-and-meta-analysis
#12
Cordula M Felix, Victor J van den Berg, Sanne E Hoeks, Jiang Ming Fam, Mattie Lenzen, Eric Boersma, Peter C Smits, Patrick W Serruys, Yoshinobu Onuma, Robert Jan M van Geuns
BACKGROUND: Bioresorbable Vascular Scaffolds (BVS) were introduced to overcome some of the limitations of drug-eluting stent (DES) for PCI. Data regarding the clinical outcomes of the BVS versus DES beyond 2 years are emerging. OBJECTIVE: To study mid-term outcomes. METHODS: We searched online databases (PubMed/Medline, Embase, CENTRAL), several websites, meeting presentations and scientific session abstracts until August 8th, 2017 for studies comparing Absorb BVS with second-generation DES...
2018: PloS One
https://www.readbyqxmd.com/read/29741484/comparison-of-acute-thrombogenicity-for-magnesium-versus-stainless-steel-stents-in-a-porcine-arteriovenous-shunt-model
#13
Michael J Lipinski, Eduardo Acampado, Qi Cheng, Lila Adams, Sho Torii, Jiaxiang Gai, Rebecca Torguson, David G Hellinga, Michael Joner, Claus Harder, Philine Zumstein, Aloke V Finn, Frank D Kolodgie, Renu Virmani, Ron Waksman
Aims The aetiology for reduced thrombogenicity of the Magmaris resorbable magnesium scaffold (RMS) when compared with the Absorb bioresorbable vascular scaffold remains unclear. We therefore investigated whether the Magmaris RMS has platelet-repelling properties by comparing its acute thrombogenicity with an equivalent stainless steel stent in an arteriovenous shunt model. Methods and Results An ex vivo porcine carotid jugular arteriovenous shunt was established and connected to Sylgard tubing containing the Magmaris RMS with sirolimus-eluting PLLA coating and an equivalent 316L stainless steel stent with sirolimus-eluting PLLA coating...
May 8, 2018: EuroIntervention
https://www.readbyqxmd.com/read/29732926/imaging-guided-pre-dilatation-stenting-post-dilatation-ipsp-a-protocolized-approach-highlighting-the-importance-of-intravascular-imaging-for-implantation-of-bioresorbable-scaffolds
#14
Ziad A Ali, Keyvan Karimi Galougahi, Richard Shlofmitz, Akiko Maehara, Gary S Mintz, Alexandre Abizaid, Daniel Chamié, Jonathan Hill, Patrick W Serruys, Yoshinobu Onuma, Gregg W Stone
The advent of the fully bioresorbable vascular scaffold (BVS) is the latest step in a series of advancements in the design of intracoronary stents over the past few decades. The novelty of this technology is in providing temporary vessel scaffolding and local antiproliferative therapy to prevent neointimal hyperplasia after percutaneous coronary intervention followed by gradual resorption of the scaffold to restore the native vessel anatomy and physiology-a process termed vascular reparative therapy. Areas covered: The first generation of BVS has not been able to fully match the high benchmark in safety and efficacy set by contemporary metallic drug-eluting stents...
May 7, 2018: Expert Review of Cardiovascular Therapy
https://www.readbyqxmd.com/read/29699747/meta-analysis-comparing-outcomes-after-everolimus-eluting-bioresorbable-vascular-scaffolds-versus-everolimus-eluting-metallic-stents-in-patients-with-acute-coronary-syndromes
#15
Roberta De Rosa, Angelo Silverio, Attilio Varricchio, Giuseppe De Luca, Marco Di Maio, Ilaria Radano, Marta Belmonte, Maria Carmen De Angelis, Elisabetta Moscarella, Rodolfo Citro, Federico Piscione, Gennaro Galasso
Acute coronary syndromes (ACS) may represent an intriguing clinical scenario for implantation of bioresorbable vascular scaffold (BRS). Nevertheless, the knowledge about the performance of these devices in patients with ACS is limited. Therefore, we performed a meta-analysis of clinical studies aiming to assess the safety and efficacy of everolimus-eluting-BRS versus everolimus-eluting-metallic stents (EES) in ACS patients undergoing percutaneous coronary intervention. Six studies enrolling 2,318 patients were included and analyzed for the risk of primary safety outcome (stent or scaffold thrombosis [ST/ScT]), primary efficacy outcome (target lesion revascularisation [TLR]), and secondary outcomes (myocardial infarction, cardiac death, all-cause death)...
July 1, 2018: American Journal of Cardiology
https://www.readbyqxmd.com/read/29699615/long-term-assessment-of-bioresorbable-coronary-scaffolds-disappearing-stents-reappearing-atherosclerosis
#16
EDITORIAL
Stephan Windecker, Raffaele Piccolo, Yasushi Ueki
No abstract text is available yet for this article.
May 1, 2018: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/29696533/tirofiban-positively-regulates-%C3%AE-1-integrin-and-favours-endothelial-cell-growth-on-polylactic-acid-biopolymer-vascular-scaffold-bvs
#17
Arturo Giordano, Simona Romano, Nicola Corcione, Giacomo Frati, Giuseppe Biondi Zoccai, Paolo Ferraro, Stefano Messina, Stefano Ottolini, Maria Fiammetta Romano
An unexpectedly high incidence of thrombosis in patients that received the polylactic acid bioresorbable vascular scaffold (BVS) suggests a delayed/incomplete endothelial repair with this stent. The anti-platelet agent tirofiban stimulates endothelial cell migration and proliferation, mediated by VEGF production. We investigated the tirofiban effect on the migration and adhesion of endothelial cells to BVS, in vitro. We performed human umbilical endothelial cell (HUVEC) cultures in the presence of BVS. Tirofiban, similarly to VEGF, increased the ability of HUVEC to grow on the vascular scaffold, compared to unstimulated or abciximab-treated cells...
June 2018: Journal of Cardiovascular Translational Research
https://www.readbyqxmd.com/read/29687699/merging-the-properties-of-a-sirolimus-coated-balloon-with-those-of-a-bioresorbable-polymer-sirolimus-eluting-stent-to-address-the-diabetes-issue-results-from-the-en-abl-multicenter-registry
#18
Luca Testa, Sameer Dani, Devang Desai, Rashmit Pandya, Pritesh Parekh, Nirav Bhalani, Arvind Sharma, Chirag Seth, Manish Doshi, Prakash Sojitra, Poonam Chodvadiya, Gopee Dutta, Francesco Bedogni
BACKGROUND: Patients with diabetes mellitus (DM) have poorer outcomes after percutaneous coronary intervention than patients without diabetes. The Abluminus DES+TM drug-eluting stent (DES) features a novel technology of fusion coating of PLLA bioresorbable polymer on both the abluminal surface of the stent and exposed parts of the balloon. AIM: To evaluate the efficacy/safety profile of the Abluminus DES+ in an all-comers population with minimal exclusion criteria and with a specific focus on diabetic patients...
April 20, 2018: Minerva Cardioangiologica
https://www.readbyqxmd.com/read/29661987/review-of-the-latest-percutaneous-devices-in-critical-limb-ischemia
#19
REVIEW
Leila Haghighat, Sophia Elissa Altin, Robert R Attaran, Carlos Mena-Hurtado, Christopher J Regan
Critical limb ischemia (CLI) is a terminal stage of peripheral arterial disease that, in the absence of intervention, may lead to lower extremity amputation or death. Endovascular interventions have become a first-line approach to the management of CLI and have advanced considerably within the past decade. This review summarizes the types of percutaneous devices and the techniques that are available for the management of CLI and the data supporting their use. These include devices that establish and maintain vessel patency, including percutaneous transluminal angioplasty, drug-coated balloons, bare metal stents, drug-eluting stents, bioresorbable vascular scaffolds, and atherectomy; devices that provide protection from embolization; and, cell-based therapies...
April 14, 2018: Journal of Clinical Medicine
https://www.readbyqxmd.com/read/29656280/real-world-bioresorbable-vascular-scaffold-experience-compared-with-second-generation-metallic-drug-eluting-stents-in-complex-coronary-lesions
#20
Naotaka Okamoto, Hiroshi Ueda, Takahiro Yoshimura, Surbhi Chamaria, Samit Bhatheja, Yuliya Vengrenyuk, Samaneh Rabiei, Yonandy Barrientos, Vishal Kapur, Nitin Barman, Joseph Sweeny, Usman Baber, Roxana Mehran, Samin K Sharma, Annapoorna S Kini
OBJECTIVES: The aim of the study was to compare the acute outcomes of Absorb bioresorbable vascular scaffolds (BVS) and second-generation drug-eluting stent (DES) implantation in routine clinical practice. There is a paucity of data regarding BVS use in a real-world patient population. METHODS: The study population comprised 40 consecutive patients who underwent percutaneous coronary intervention (PCI) with BVS implantation at a tertiary-care center in New York, New York between July and December of 2016...
April 15, 2018: Journal of Invasive Cardiology
keyword
keyword
116611
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"